ArticleOncology letters2025
Multidisciplinary strategies including local treatment to achieve drug-free status after atezolizumab plus bevacizumab treatment in hepatocellular carcinoma.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atezolizumab plus bevacizumab (AteBev) is used as a first-line treatment for advanced hepatocellular carcinoma (HCC). Combining AteBev with sequential local treatment holds potential; however, optimal timing, modality and continuation of systemic chemotherapy remain undetermined. In the present study, a retrospective analysis of 123 patients with HCC treated with AteBev at two institutions was performed. Patients with no apparent residual lesions after sequential local treatment or AteBev treatment alone were followed up without any systemic chemotherapy ('drug-free' cohort). Outcomes focused on the impact of achieving 'drug-free' status, with timing assessed based on tumor size and α-fetoprotein levels. The results revealed that serum α-fetoprotein levels and tumor shrinkage plateaued at ~3 and 6 months post-AteBev treatment, respectively. Patients achieving 'drug-free' status demonstrated prolonged median survival (P<0.001) and progression-free survival (P<0.001), comparable with patients with 'clinical complete response' or 'drug-off' statuses. Moreover, particle radiotherapy was the most common local treatment modality. In conclusion, achieving a 'drug-free' status was associated with favorable prognoses. Optimal timing for sequential local treatment is suggested as 3-6 months after AteBev initiation, with multidisciplinary strategies to achieve 'drug-free' status offering a promising option for the treatment of advanced HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.